INVA Q4 2024 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$92M+7.0% YoY

Gross Profit

$85M92.2% margin

Operating Income

$43M47.0% margin

Net Income

$20M22.1% margin

EPS (Diluted)

$0.24

QoQ Revenue Growth

+2.6%

Cash Flow

Operating Cash Flow

$59M

Free Cash Flow

$55M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$610M

Stockholders' Equity

$691M

Cash & Equivalents

$305M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$92M	$86M	+7.0%
Gross Profit	$85M	$73M	+16.4%
Operating Income	$43M	$38M	+15.0%
Net Income	$20M	$62M	-67.0%

Revenue Segments

Royalty

$63M68%

Product

$29M32%